All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Synendos Therapeutics AG is poised for a fresh attempt at drugging the endogenous endocannabinoid system after raising CHF20 million (US$21.8 million) to take its lead program into clinical development.